.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

John Molina, MD, MEd

Articles

Clinical Trials and Real-World Data on Brexu-Cel

January 30th 2025

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Introduction to CAR T-Cell Therapies in R/R ALL

January 30th 2025

Panelists discuss how the recent FDA approval of obecabtagene autoleucel (obe-cel) for relapsed/refractory acute lymphoblastic leukemia (R/R ALL) adds to the existing chimeric antigen receptor (CAR) T-cell therapies, with a focus on the differences in their mechanisms, structures, and FDA indications.